FDA Enforcement Class III Terminated

ADVIA Centaur BNP Assay for in vitro diagnostic use in the quantitative determination of B-type Natriuretic Peptide (BNP) in human plasma using the ADVIA Centaur, Centaur XP, Centaur CP Systems; Catalog Numbers: Cat No. 02816138/SMN 10309044 (100 test) 02816634/SMN 10309045 (500 test)

Recall: Z-0229-2015 · Reported November 26, 2014

Enforcement

Recall Number
Z-0229-2015
Event ID
69461
Classification
Class III
Status
Terminated
Product Type
Devices
Firm
Siemens Healthcare Diagnostics, Inc
Voluntary / Mandated
Voluntary: Firm initiated
Initial Notification
Letter
Report Date
November 26, 2014
Initiation Date
October 6, 2014
Classification Date
November 19, 2014
Termination Date
July 22, 2015
Address
333 Coney St, N/A, East Walpole, MA, 02032-1516, United States

Description

ADVIA Centaur BNP Assay for in vitro diagnostic use in the quantitative determination of B-type Natriuretic Peptide (BNP) in human plasma using the ADVIA Centaur, Centaur XP, Centaur CP Systems; Catalog Numbers: Cat No. 02816138/SMN 10309044 (100 test) 02816634/SMN 10309045 (500 test)

Reason

Siemens Healthcare Diagnostics has confirmed that approximately 2000 ReadyPacks from the ADVIA Centaur¿ Systems BNP reagent contains an ADVIA Centaur Systems FT4 human-readable side label.

Code Info

Lot 038174: 100 Test - 43305174 and 43278174; 500 Test - 43306174 and 43279174.

Distribution

Worldwide Distribution - US Nationwide including Puerto Rico; and countries of: Canada, Austria, Belgium, Czech Republic, Denmark, Estonia, Finland, France, Fren.Polynesia, Germany, Great Britain, Greece, Guadeloupe, Italy, Latvia, Lithuania, Netherlands, Norway, Poland, Portugal, Reunion, Russian Fed., Slovakia, Slovenia, Spain, Switzerland, Turkey, Unit.Arab Emir., AR, AU, BR, CL, CN, CR, IN, JP, KR, LK, MY, SG, TW, UY, VN, and ZA.

Quantity

100 test - 4,600 kits; 500 test - 1,878 kits